Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis
| Autor: | Makis, A. C., Galanakis, E., Hatzimichael, E. C., Papadopoulou, Z. L., Siamopoulou, A., Bourantas, K. L. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Male
Anti-Infective Agents/administration & dosage/therapeutic use Interleukin-2 Receptor alpha Subunit Infant Rifampin/administration & dosage/therapeutic use Brucellosis/*drug therapy/microbiology Receptors Interleukin-2/*blood Treatment Outcome Solubility Predictive Value of Tests Child Preschool Humans Drug Therapy Combination Female Child Trimethoprim-Sulfamethoxazole Combination/administration & dosage/therapeutic use Interleukin-2/blood |
| Popis: | OBJECTIVES AND METHODS: Brucellosis is characterized by chronicity and relapses despite efficacious treatment. Cytokines and especially the Th1/Th2 balance may be involved in the susceptibility or resistance to the Brucella species. In order to identify predictors of treatment outcome, we measured the pre and posttreatment levels of serum interleukin-2 (IL-2) and soluble IL-2 receptor alpha (sIL-2Ralpha) in 20 children with brucellosis. All children were treated for 6 weeks and three of them (15%) presented with a relapse at 2, 3 and 8 months after treatment had ended. RESULTS: Serum IL-2 levels, both pretreatment and posttreatment, did not significantly differ between patients and controls. By contrast, pretreatment sIL-2Ralpha levels were significantly higher in patients (P< or =0.0001) than in controls. sIL-2Ralpha levels significantly declined (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|